dc.contributor.author | Fielding, AK | en_US |
dc.contributor.author | Rowe, JM | en_US |
dc.contributor.author | Buck, G | en_US |
dc.contributor.author | Foroni, L | en_US |
dc.contributor.author | Gerrard, G | en_US |
dc.contributor.author | Litzow, MR | en_US |
dc.contributor.author | Lazarus, H | en_US |
dc.contributor.author | Luger, SM | en_US |
dc.contributor.author | Marks, DI | en_US |
dc.contributor.author | McMillan, AK | en_US |
dc.contributor.author | Moorman, AV | en_US |
dc.contributor.author | Patel, B | en_US |
dc.contributor.author | Paietta, E | en_US |
dc.contributor.author | Tallman, MS | en_US |
dc.contributor.author | Goldstone, AH | en_US |
dc.date.accessioned | 2024-01-04T12:07:49Z | |
dc.date.issued | 2014-02-06 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/93362 | |
dc.description.abstract | The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (pre-imatinib cohort). In 2003 imatinib was introduced as a single-agent course following induction (N = 86, late imatinib). In 2005 imatinib was added to the second phase of induction (N = 89, early imatinib). The complete remission (CR) rate was 92% in the imatinib cohort vs 82% in the preimatinib cohort (P = .004). At 4 years, the overall survival (OS) of all patients in the imatinib cohort was 38% vs 22% in the preimatinib cohort (P = .003). The magnitude of the difference between the preimatinib and imatinib cohorts in event-free survival (EFS), OS, and relapse-free survival (RFS) seen in univariate analysis was even greater in the multivariate analysis. In the preimatinib cohort, 31% of those starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the imatinib cohort. A Cox multivariate analysis taking alloHSCT into account showed a modest additional benefit to imatinib (hazard ratio for EFS = 0.64, 95% confidence interval 0.44-0.93, P = .02), but no significant benefit for OS and RFS. Adding imatinib to standard therapy improves CR rate and long-term OS for adults with ALL. A proportion of the OS benefit derives from the fact that imatinib facilitates alloHSCT. This trial was registered at clinicaltrials.gov as NCT00002514. | en_US |
dc.format.extent | 843 - 850 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Blood | en_US |
dc.subject | Adolescent | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Benzamides | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | Combined Modality Therapy | en_US |
dc.subject | Female | en_US |
dc.subject | Follow-Up Studies | en_US |
dc.subject | Hematopoietic Stem Cell Transplantation | en_US |
dc.subject | Humans | en_US |
dc.subject | Imatinib Mesylate | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Neoplasm Recurrence, Local | en_US |
dc.subject | Philadelphia Chromosome | en_US |
dc.subject | Piperazines | en_US |
dc.subject | Precursor Cell Lymphoblastic Leukemia-Lymphoma | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Pyrimidines | en_US |
dc.subject | Remission Induction | en_US |
dc.subject | Survival Rate | en_US |
dc.subject | Transplantation, Homologous | en_US |
dc.subject | Young Adult | en_US |
dc.title | UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1182/blood-2013-09-529008 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/24277073 | en_US |
pubs.issue | 6 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 123 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |